

# ICPO Theranostics FAP Summit

## Targeting the Tumor Microenvironment and Beyond

Friday 4 & Saturday 5 November 2022



### PRELIMINARY PROGRAMME

Subject to change | Revision Oct 04, 2022 | All stated times correspond to Central European Time

**FRIDAY, 4 NOVEMBER 2022**

**What is FAP? History of FAP - Diagnostics using FAP - FAP Innovation & FAP PET Reading**

16:00 – 16:10 **Welcome**  
CET

#### **SESSION I: Introduction to FAP**

16:10 – 16:25 **What is FAP? Genesis to today**  
CET Andrew Scott, Australia

16:25 – 16:40 **LRRC15 - a TGFB-driven FAP-like protein**  
CET David Ulmert, USA

16:40 – 16:55 **FAP in Tumor micro environment, Molecular Pathology Perspective**  
CET Ralph Wirtz, Germany

16:55 – 17:10 **Pharmacologic targeting of master regulators of the tumor microenvironment**  
CET Andrea Califano, USA

#### **SESSION II: Diagnostics for Oncology**

17:15 – 17:30 **FAPi PET Next Wave of Molecular Imaging**  
CET Frederik Giesel, Germany

17:30 – 17:45 **FAPi is not the new FDG**  
CET Jeremie Calais, USA

17:45 – 18:00 **FAPi in FDG negative / low metabolic tumors**  
CET Andrea Farolfi, Italy and USA

18:05 – 18:15 **Break**

#### **SESSION III: Diagnostics for Non-Oncology**

18:15 – 18:30 **Cardiac applications of FAPi PET**  
CET Johanna Diekmann, Germany

18:30 – 18:45 **FAP imaging in immune-mediated inflammatory diseases**  
CET Christian Schmidkonz, Germany

18:45 – 19:00 **Liver fibrosis and fibrogenesis**  
CET Ali Pirasteh, USA

# ICPO Theranostics FAP Summit

## Targeting the Tumor Microenvironment and Beyond

Friday 4 & Saturday 5 November 2022



### FRIDAY, 4 NOVEMBER 2022

#### What is FAP? History of FAP - Diagnostics using FAP - FAP Innovation & FAP PET Reading

##### PANEL I: FAP DIAGNOSTIC

19:05 – 19:55 **Clinical utility and outperformance of FAPi diagnostic**  
CET Moderator: Ken Herrmann, Germany

19:55 – 20:05 **Break**  
CET

##### SESSION IV: Preclinical & Chemistry, Emerging Theranostics

20:05 – 20:20 **FAP-inhibitors and substrates: a medicinal chemistry perspective**  
CET Pieter van der Veken, Belgium

20:20 – 20:35 **Development of FAP ligands and clinical transfer**  
CET Uwe Haberkorn, Germany

20:35 – 20:50 **Discovery and development of ultra-high performance FAP targeting agents**  
CET Dario Neri / Samuele Cazzamalli, Italy

20:50 – 21:05 **FAP ligands and its challenges in Theranostics**  
CET Frank Rösch, Germany

##### PANEL II: FAP INNOVATION

21:10 – 22:00 **FAP as a biomarker, exploration of radionuclide labeling utility for FAP compounds**  
CET Moderator: Klaus Kopka, Germany

##### BONUS

22:00 – 22:30 **Presentations of Clinically Interesting FAP PET Cases**  
CET Moderator: Rodney Hicks, Australia

# ICPO Theranostics FAP Summit

## Targeting the Tumor Microenvironment and Beyond

Friday 4 & Saturday 5 November 2022



### SATURDAY, 5 NOVEMBER 2022

#### FAP Therapy Innovation and Clinical Profile - FAP in clinical trials – Patient Access and Global Perspective

16:00 – 16:10  
CET **Welcome**

#### **SESSION V:** Innovation in Radioligand Therapeutics

16:10 – 16:25  
CET **How to develop FAP ligands**  
John Babich, USA

16:25 – 16:40  
CET **Evans blue modified FAPI (EB-FAPI) developed by Yantai LNC Biotech**  
Shawn Chen, Singapore

16:40 – 16:55  
CET **3B Pharma developments**  
Jan Lennart von Hacht, Germany

16:55 – 17:10  
CET **Fibroblast activation protein-based theranostics in cancer research: Improvement in the FAPI probe and FAP-targeted radionuclide therapy**  
Haojun Chen, China

17:10 – 17:25  
CET **FAP protein engineering developments**  
Chris Carol-Bremer, Germany

#### **SESSION VI:** Non-Radioligand Therapeutics

17:30 – 17:45  
CET **Pre-clinical Development of AVA6000 – a FAP targeted chemotherapeutic agent in Phase I**  
Fiona McLaughlin, United Kingdom

17:45 – 18:00  
CET **Therapeutic bispecific antibodies and fusion proteins targeting FAP,**  
Christian Klein, Switzerland

18:00 – 18:15  
CET **TBA**  
Ellen Pure, USA

18:15 – 18:25  
CET **Break**

#### **PANEL III:** FAP THERAPY

18:25 – 19:20  
CET **How to raise the clinical profile of FAP Therapeutics? What is the impact of FAP on patient management in selected clinical cases**  
Moderator: Elcin Zan, USA

# ICPO Theranostics FAP Summit

## Targeting the Tumor Microenvironment and Beyond

Friday 4 & Saturday 5 November 2022



### SATURDAY, 5 NOVEMBER 2022

#### Therapy using FAP - FAP in clinical trials - Patient Access and regulatory - Ask the experts

##### SESSION VII: Clinical Trials, Emerging Therapeutics/Diagnostics

19:20 – 19:35 CET	<b>PTRT, FAP peptide targeted radioligand therapy: clinical experience in different adenocarcinomas</b> Richard P. Baum, Germany
19:35 – 19:50 CET	<b>FAPI clinical development updates by Sofie Biosciences</b> Sherly Mosessian, USA
19:50 – 20:05 CET	<b>177Lu-FAP-2286 in Patients with Advanced or Metastatic Solid Tumours: Updated Data From a Phase 1/2 Study Investigating Safety, Pharmacokinetics, Dosimetry, and Preliminary Antitumour Activity (LuMIERE)</b> Curt Wolfgang, USA
20:05 – 20:20 CET	<b>FRONTIER: A Phase 1 Theranostic Study of FAP-targeted [Lu-177]-PNT6555 in Patients with Select Solid Tumors</b> Richard Cioci, Canada
20:20 – 20:35 CET	<b>177Lu-DOTAGA-SA-FAPI-Dimer - New hope for Radioiodine Refractory metastatic differentiated Thyroid Cancer Patients</b> C. S. Bal, India

20:40 – 20:50  
CET **Break**

##### SESSION VIII: Patient access and future regulatory landscape, FAP Radiopharmaceuticals in a global perspective

20:50 – 21:05 CET	<b>Perspective on FAP Patient Access</b> Josh Mailman, USA
21:05 – 21:20 CET	<b>Current status and future perspective in Japan</b> Tadashi Watabe, Japan
21:20 – 21:35 CET	<b>FAP targeting radiopharmaceuticals in Latin America: Current state and future perspective</b> Vasko Kramer, Chile
21:35 – 21:50 CET	<b>African perspective</b> Mike Sathekge, South Africa

##### PANEL IV: ROUNDTABLE

21:55 – 22:25  
CET **Future Outlook on FAP**  
Moderator: Frederik Giesel, Germany

##### CLOSING

22:25 – 22:30  
CET **Closing words**